We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
The monoclonal antibody Ibalizumab has shown significant antiviral activity against multidrug resistant HIV infections, according to the results of a phase III clinical trial.